The short answer
Retatrutide is a 39-residue synthetic peptide built on a modified GIP scaffold, with a C20 fatty diacid conjugated through a γGlu-2xOEG linker at Lys17. The lipid binds serum albumin, extending half-life; the substitutions across the backbone create balanced activity at three receptors.
Key facts
- Residues
- 39
- Backbone
- Modified GIP scaffold
- Lipidation site
- Lys17
- Linker
- γGlu-2xOEG
- Fatty acid
- C20 diacid
- Receptors
- GIPR, GLP-1R, GCGR
- Primary reference
- Coskun, Cell Metab 2022
Why the backbone is GIP
This is the design decision that defines the molecule, and it is the same one Lilly made with tirzepatide. Rather than starting from GLP-1 and adding activity, both compounds start from GIP and engineer in the others. The three receptors (GIP, GLP-1 and glucagon) belong to one structurally related family, which is what makes a single scaffold capable of engaging all of them plausible at all.
What balanced agonism means
Balanced does not mean equal. It means the potencies at the three receptors sit within a range where all three contribute meaningfully at achievable concentrations, rather than one dominating so completely that the others are irrelevant. Achieving that across three related but distinct receptors, from one sequence, is the hard part of the design.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The lipid and what it does
A C20 fatty diacid attached at Lys17 through a γGlu-2xOEG spacer. The diacid binds reversibly to serum albumin, which is too large to be filtered by the kidney and shields the peptide from proteases. This is the same strategy semaglutide uses with a C18 diacid and liraglutide with C16 palmitic acid, with chain length tuning the strength of binding and therefore the half-life.
Why the linker is not padding
The γGlu-2xOEG spacer sets the distance and flexibility between the albumin-binding lipid and the receptor-binding peptide. Get it wrong and albumin binding sterically blocks the peptide from reaching its receptors, or the lipid cannot reach albumin. It is a real design parameter rather than a connector.
Why Lys17 specifically
Lipidation needs a lysine side-chain amine to attach to, and it needs to be at a position where a bulky substituent does not interfere with receptor contact. Position 17 satisfies both. The same logic places semaglutide's chain at Lys26 and tirzepatide's at Lys20, each chosen for the same reasons within a different sequence.
Where the sequence is published
Coskun and colleagues described the discovery and characterisation of LY3437943 in Cell Metabolism in September 2022, and the sequence has appeared in Eli Lilly patent filings. That paper is the primary structural reference for anything in this article.
Frequently asked questions
How long is retatrutide?
39 residues, plus a C20 fatty diacid conjugated at Lys17 through a γGlu-2xOEG linker.
Why build it on GIP rather than GLP-1?
The three target receptors belong to one related family, and the GIP scaffold proved the workable starting point. It is the same choice Lilly made for tirzepatide.
What does the fatty acid do?
It binds serum albumin reversibly, which prevents renal filtration and shields the peptide from proteases, extending half-life.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al., LY3437943. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Semaglutide, for lipidation comparison (CID 56843331)pubchem.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- What Does "Reta" Mean?Reta is informal shorthand for retatrutide. What the full name encodes under WHO INN conventions, and why the -tide suffix matters.
- What "Reta" on a Label Actually Tells YouAn informal term for material sold as retatrutide for laboratory research. What the name does and does not tell you about the contents.
- Retatrutide vs Mounjaro, Ozempic and WegovyMounjaro is tirzepatide, Ozempic is semaglutide, and retatrutide is neither. One, two and three receptors - and why the headline figures rarely compare.
- Is Retatrutide FDA Approved? Regulatory Status ExplainedRetatrutide is not FDA approved. It is an investigational peptide in the Phase 3 TRIUMPH programme. Current EMA, MHRA and FDA regulatory status explained.
- Retatrutide Molecular Structure and PropertiesA lipidated 39-mer supplied as a white lyophilised powder. What the structure implies for solubility, handling and analysis.